Instructions for Lactogynal (lactobacillus acidophilus) 14 capsules
English Product Name
Lactogynal
Release Form
Capsules vaginal
Description Lactogynal
Vaginal capsules are transparent, gelatin, size "0"; the contents of the capsules are light yellow powder with a brownish tint of color.
1 caps.
Lyophilized culture of L. casei rhamnosus Doderleini lactobacilli at least 1×108 COE
Auxiliary substances: magnesium stearate - 3.41 mg, lactose monohydrate - 5.59 mg, components of the protective drying medium (potato starch, lactose monohydrate, sodium glutamate, sodium thiosulfate).
Capsule shell composition: gelatin.
14 pcs - colorless glass vials (1) - cardboard packs.
Note:
The composition of the protective drying medium is: potato starch (~41% of the mass of the lyophilizate), lactose monohydrate (~20.6% of the mass of the lyophilizate), sodium glutamate (~4.5% of the mass of the lyophilizate), sodium thiosulfate (~26.8% of the mass of the lyophilizate).
ATX codes Lactogynal
G01AX14 Lactobacteria
Clinical and pharmacological groups / Group affiliation
Drug regulating the balance of vaginal flora
Active ingredient
lyophilized culture of Lactobacillus casei rhamnosus Doderleini lactobacilli
Pharmacotherapeutic group Lactogynal
Eubiotic
Retention conditions
The drug should be kept out of reach of children at temperatures not exceeding 25°C.
Expiration date
Shelf life - 2 years. Do not apply after expiry date.
Pharmacological effect Lactogynal
Lactobacillus casei are gram-positive rod-shaped, anaerobic, nonspore-forming bacteria. They are part of the normal obligate flora of the mouth, intestine, vulva, and vagina of humans. Along with other lactobacilli such as Lactobacillus acidophilus, Lactobacillus fermentum, Lactobacillus cellobiosum, Lactobacillus casei are present in the normal flora of the vulva and vagina in women.
Live rod colonization of the vagina Lactobacillus casei rhamnosus doderleini creates a physiologic-like environment in the vagina. The lactojinal® strain Lactobacillus casei rhamnosus doderleini has antagonistic activity against a wide range of pathogenic and opportunistic bacteria, improves local metabolic processes, and promotes restoration of natural local immunity.
When lactojinal® is injected into the vagina, the capsule’s gelatin sheath dissolves, releasing the lyophilized culture of live lactobacilli.
In vitro studies have shown that Lactobacillus casei rhamnosus doderleini promotes a decrease in pH in the vagina within hours of administration, restoring the natural microflora.
Lactobacterial deficiency is an important factor in the development of candidal vulvovaginitis. Lactobacteria act as the physiologic antagonists of Candida yeast fungi, suppressing their growth and reproduction.
The results of clinical studies confirm the effectiveness of the drug Lactojinal® in restoring normal microflora of the vagina and preventing candidal vulvovaginitis after antifungal therapy.
In vitro and in vivo studies have shown that the Lactobacillus casei subsp. rhamnosus LCR35 strain is resistant to some antimicrobial drugs and may enhance the effects of antibiotics, which may increase the effectiveness of bacterial vaginosis therapy when combined with lactojinal® and clindamycin.
Testimony Lactogynal
restoration of normal vaginal flora for
Bacterial vaginosis from the first day of antimicrobial therapy or immediately after it is completed
Preparation for routine gynecological operations;
Antenatal training for pregnant women at risk of bacterial vaginosis
prevention of recurrence of candidal vulvovaginitis (including exacerbations of recurrent vulvovaginal candidiasis) after local and/or systemic antifungal therapy.
Method of application Lactogynal:
The drug is administered by intravaginal administration of a capsule premoistened with a small amount of water for faster dissolution.
Bacterial vaginosis requires 1 capsule in the morning and evening for 7 days, 1 capsule daily for 14 days after completion of antimicrobial therapy, or 1 capsule daily for 14 days after initiation of antimicrobial therapy to restore normal vaginal flora.
When preparing for elective gynecologic surgery or prenatal training for pregnant women with an increased risk of bacterial vaginosis, 1 capsule in the morning and evening for 7 days or 1 capsule daily for 14 days as part of complex therapy is recommended.
Dosing should be adjusted based on clinical response. To prevent recurrences of candidal vulvovaginitis, 1 capsule per night is recommended after previous antifungal therapy. The duration of the therapy course is determined by the doctor, not exceeding 21 days. Repeated courses are decided on individual indications.
If there is no improvement after treatment, deterioration, or new symptoms appear, consult a doctor. It should be used only according to the instructions, method of use and dosage described in the instructions.
Nosology Lactogynal (ICD codes)
N76
Other inflammatory diseases of vagina and vulva
N89.8
Other noninflammatory diseases of vagina
Y40.7
Systemic antifungal antibiotics
Y40.9
Unspecified systemic antibiotics
Z29.8
Other specified preventive measures
Z51.4
Preparatory procedures for follow-up treatment or examination, not elsewhere classified